Lv2
130 积分 2021-12-06 加入
Upregulation of Myt1 promotes acquired resistance of cancer cells to Wee1 inhibition
6天前
已完结
Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer
6天前
已完结
AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
1个月前
已完结
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
1个月前
已完结
The ovarian cancer drug market
2个月前
已完结
A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study
2个月前
已完结
PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer
2个月前
已完结
The Forefront of Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer in China: A Review of Updated Evidence With PARP Inhibitors
2个月前
已完结
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
2个月前
已完结
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
3个月前
已完结
皖公网安备34019202002308
